Trial Profile

A phase III clinical trial to investigate cemsidomide and dexamethasone in combination with a BCMA BiTE with other MM agents for Second line of therapy or later in patients with relapsed/refractory multiple myeloma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jan 2026 According to C4 Therapeutics media release, the company plans to initiate the trial by early 2028.
14 Nov 2025 New trial record
20 Sep 2025 According to C4 Therapeutics media release, the C4 plans to initiate a Phase 1b trial, If the data are supportive, C4T will advance this combination regimen directly into a single, randomized controlled Phase 3 study. This Phase 3 study will be designed to support the full approval for both the cemsidomide and dexamethasone pathway.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com